B

Bavarian Nordic A/S
CSE:BAVA

Watchlist Manager
Bavarian Nordic A/S
CSE:BAVA
Watchlist
Price: 162.7 DKK -1.39% Market Closed
Market Cap: 12.8B DKK

EV/EBITDA
Enterprise Value to EBITDA

6.2
Current
6.6
Median
3.9
Industry
Lower than median
Higher than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
6.2
=
Enterprise Value
10.9B DKK
/
EBITDA
1.8B DKK
Market Cap EV/EBITDA
DK
Bavarian Nordic A/S
CSE:BAVA
12.7B DKK 6.2
FR
Pharnext SCA
OTC:PNEXF
6T USD -210 934.3
US
Abbvie Inc
NYSE:ABBV
371.2B USD 17.1
US
Amgen Inc
NASDAQ:AMGN
167.2B USD 16.5
US
Gilead Sciences Inc
NASDAQ:GILD
132.3B USD 10.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
130.1B USD 26.6
US
Epizyme Inc
F:EPE
94.1B EUR -535.6
AU
CSL Ltd
ASX:CSL
123B AUD 17.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
72.1B USD 10.7
US
Seagen Inc
F:SGT
39.3B EUR -61.2
NL
argenx SE
XBRU:ARGX
34B EUR 327.6
EBITDA Growth EV/EBITDA to Growth
DK
B
Bavarian Nordic A/S
CSE:BAVA
Average EV/EBITDA: 54.1
6.2
-16%
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -210 934.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
17.1
13%
1.3
US
Amgen Inc
NASDAQ:AMGN
16.5
14%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
10.8
6%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.6
16%
1.7
US
E
Epizyme Inc
F:EPE
Negative Multiple: -535.6 N/A N/A
AU
CSL Ltd
ASX:CSL
17.4
12%
1.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
10.7
17%
0.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.2 N/A N/A
NL
argenx SE
XBRU:ARGX
327.6
168%
1.9

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
7
2-Years Forward
EV/EBITDA
3.9
3-Years Forward
EV/EBITDA
5.7